10 results
The study will compare the change in cutaneous cellular oxygen availability, measured as mitochondrial PO2 (mitoPO2) between a fluid challenge and a blood transfusion in chronic anemia patients.
The objective of this study is to evaluate the additional value of novel anemia markers (RET-HE, RPI, sTfR, sTfR/log(ferritin), transferrin/log(ferritin)) in a prospective, randomized study design. Our hypothesis is that the novel anemia markers can…
to analyse the applicability of neutron activation analysis in measuring the absorption of a trace dose of the stable 58 Fe isotope orally given as ironsulphate
We aim to determine whether the change in Ret- He, RBC- He and hepcidin concentration to one or two weeks iron supplementation therapy predicts the increase in hemoglobin concentration after 6 weeks of oral iron supplementation therapy in anemic…
Serum hepcidin levels are elevated in hemodialysis patients and may contribute to functional iron impairment and thus to ESA-resistance. Kinetics of hepcidin in hemodialysis patients has not been studied in detail. This study is designed to provide…
The first objective is to explore whether epo regulation and expression, at the age of two weeks after birth and three to six months post-term, are associated with the course of Hb levels. Furthermore, we will assess if epo regulation and expression…
To measure a change in Hemoglobin levels upon a change in posture from supine to upright in in ICU patients.
Regarding the current recommended once daily dosing of oral iron (with probably less side effects than with a 3 times daily dose), and the decrease of hepcidin in patients on immunosuppressive medication, we hypothesize that patients with mild to…
The objective of this study is to validate the tHb determined by sOCT by comparing it to the tHb from invasive blood sampling. From this comparison, we aim to optimize our data analysis procedure for in vivo sOCT measurements. We also aim to…
To assess the relation between bleeding tendency (patients with WHO grade II or more) and platelet function and platelet /count in patients with hemato-oncological disease